Brucella ovis BP26 antibody and antigen (recombinant protein)

 Download 

Diagnostic anti-Brucella ovis BP26 antibodies pairs and antigen for animal health (animal Ovines/Sheep infectious disease sexually transmitted infectious disease) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Go to Ruminants disease testing products collection >>

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-VT-P043-Tg001-Ag01	Recombinant Brucella ovis BP26 protein	$3090.00
GMP-VT-P043-Tg001-Ab01	Anti-Brucella ovis BP26 mouse monoclonal antibody (mAb)	$3090.00
GMP-VT-P043-Tg001-Ab02	Anti-Brucella ovis BP26 mouse monoclonal antibody (mAb)	$3090.00
GMP-VT-P043-Tg001-Ab03	Anti-Brucella ovis BP26 human monoclonal antibody (mAb)	$3090.00
GMP-VT-P043-Tg001-Ab04	Anti-Brucella ovis BP26 human monoclonal antibody (mAb)	$3090.00

Size： 1mg | 10mg | 100mg

Product Description

Cat No.	GMP-VT-P043-Tg001-Ag01
Product Name	Recombinant Brucella ovis BP26 protein
Pathogen	Brucella ovis
Expression platform	E.coli
Isotypes	Recombinant Antigen
Bioactivity validation	Anti-Brucella ovis BP26 antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Brucella ovis level test of animal Ovines/Sheep infectious disease with sexually transmitted infectious disease.
Tag	His
Product description	Recombinant Brucella ovis BP26 proteinwas expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-VT-P043-Tg001-Ab01,GMP-VT-P043-Tg001-Ab02
Pathogen	Brucella ovis
Product Name	Anti-Brucella ovis BP26 mouse monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Recombinant Brucella ovis BP26 antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Brucella ovis antibodies in Brucella ovis level test of animal Ovines/Sheep infectious disease with sexually transmitted infectious disease.
Product description	Anti-Brucella ovis BP26 mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Brucella ovis antibodies.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-VT-P043-Tg001-Ab03,GMP-VT-P043-Tg001-Ab04
Pathogen	Brucella ovis
Product Name	Anti-Brucella ovis BP26 human monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Human lgG1
Bioactivity validation	Recombinant Brucella ovis BP26 antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Brucella ovis antibodies in Brucella ovis level test of animal Ovines/Sheep infectious disease with sexually transmitted infectious disease.
Product description	Anti-Brucella ovis BP26 mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Pathogen Information

Brucella ovis is a gram-negative bacterium belonging to the family Brucellaceae. It primarily infects sheep and goats, causing infections of the reproductive tract and resulting in epididymitis and infertility in rams. Although not pathogenic to humans, it is zoonotic and can cause occupational infections in individuals working with infected animals.

The structure of Brucella ovis is characterized by its outer membrane protein 25 (Omp25), which is involved in adhesion and invasion of host cells. Additionally, the pathogen has other proteins such as VirB and BvrR that play a critical role in virulence and regulation. In particular, VirB is involved in the secretion of effector proteins that manipulate host immune responses, while BvrR regulates gene expression in response to environmental signals.

Due to its unique structure and virulence factors, Brucella ovis can evade the host's immune system and establish chronic infections. These infections are typically asymptomatic, making it difficult to detect and control the spread of the pathogen.

Diagnostic methods for Brucella ovis include serological tests such as the Rose Bengal Test and enzyme-linked immunosorbent assay (ELISA) that detect antibodies against the pathogen in the blood. These tests have been shown to be highly specific and sensitive for diagnosing brucellosis caused by B. ovis. However, false-positive results can occur due to cross-reactivity with other Brucella species or other bacteria.

Polymerase chain reaction (PCR) can also be used to detect specific DNA sequences in samples, including those from blood, semen, and tissues. These diagnostic methods typically target conserved genes such as the omp25 gene and the IS711 family of genes, which are common among all Brucella species. In addition, real-time PCR assays have been developed that can detect B. ovis in semen samples with high sensitivity and specificity.

Treatment for Brucella ovis infections typically involves the use of antibiotics such as tetracyclines, aminoglycosides, and fluoroquinolones. However, these treatments are often ineffective in eradicating the pathogen and can lead to the development of antibiotic-resistant strains. Therefore, prevention is the key strategy for controlling the spread of B. ovis in animal populations.

Preventive measures include vaccination of animals with live attenuated or killed vaccines. These vaccines have been shown to be highly effective in reducing the incidence of B. ovis infections and associated reproductive disorders in sheep and goats. Additionally, good hygiene practices on farms can help minimize the exposure of animals to the pathogen and prevent the spread of infection.

In conclusion, Brucella ovis is a bacterium that primarily infects sheep and goats, causing infections of the reproductive tract and resulting in epididymitis and infertility in rams. The pathogen's unique structure and virulence factors enable it to evade the host's immune system, leading to chronic infections that are difficult to diagnose and control. Diagnostic methods such as serological tests and PCR have been developed to detect the pathogen in samples, while treatment and prevention strategies aim to reduce the incidence of B. ovis infections and associated reproductive disorders in animals.

About GDU